Abstract
BackgroundSecukinumab (SEC) is a human monoclonal antibody (IgG1) aimed against IL-17A, a proinflammatory cytokine involved in the pathogenesis of psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). It is already well...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
